Over the past few decades there has been remarkable progress in viral hepatitis. Beginning with discovery of the viral agents, we now have reliable methods to diagnose and monitor all hepatitis virus infections, as well significant advances in treatment and prevention. Nonetheless, important challenges remain. This supplement to Gut looks forward to the next generation of challenges in the field of viral hepatitis, and this introductory article highlights several key issues.
- Hepatitis A
- hepatitis B
- hepatitis C
- hepatitis E
- hepatitis D
Statistics from Altmetric.com
Competing interests David Thomas received donations of antiretroviral drugs from Gilead and Merck and served on a scientific advisory board for Merck.
We thank Novartis for the financial support that has made this supplement possible. As always, Gut retains sole responsibility for all editorial content.
Provenance and peer review Commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.